Elekta further strengthens its Elekta ONE software suite with acquisition of Philips treatment planning patent portfolio

Elekta and Philips have reached an agreement to transfer Philips’ patent portfolio in the radiation oncology treatment planning domain to Elekta, unlocking further innovations in radiation therapy treatment planning and workflow optimization. By integrating the technologies covered by the acquired patent portfolio, Elekta and Philips aim to offer a seamless and best-in-class transition for existing Pinnacle users to Elekta ONE Planning, including data conversion services, showcased at the upcoming ESTRO event.

In June 2021, Elekta and Philips announced their long-term strategic partnership to advance comprehensive and personalized cancer care through precision oncology solutions, from CT and MR simulation to treatment planning, preparation and delivery.

Maurits Wolleswinkel, President, Linac and Software Solutions at Elekta, said: “Thanks to continued investments over the years, our treatment planning system supports both Elekta and non-Elekta devices, including proton therapy, making Elekta ONE Planning one of the most competitive solutions in the market. At ESTRO, we will unveil exciting new capabilities, including novel scripting elements inspired by Pinnacle, demonstrating Elekta ONE’s competitive advantage.”

Martijn Hartjes, Business Leader Clinical Informatics at Philips, added: “We are pleased that we can continue to support our customers with leading solutions in radiation oncology. This is a logical next step in the strong long-term collaboration between Philips and Elekta in the radiotherapy domain to improve cancer care together.”

See a live demo of Elekta ONE, and how it will elegantly include Pinnacle-related technology, at ESTRO 2024, May 3-7 in Glasgow, UK at Elekta’s booth #440.

# # #

For further information, please contact:
Mattias Thorsson, Vice President, Head of Corporate Communications
Tel: +46 70 865 8012, e-mail: [email protected]  
Time zone: CET: Central European Time

Raven Canzeri, Global Director, Media Relations
Tel: +1 770-670-2524, e-mail: [email protected]
Time zone: ET: Eastern Time

About Elekta
As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,500 employees combine passion, science, and imagination to profoundly change cancer care. We don’t just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 40 countries and listed on Nasdaq Stockholm. For more information, visit elekta.com or follow @Elekta on “X”, formerly known as Twitter.